Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings DaShenLin Pharmaceutical Group Co., Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: DaShenLin Pharmaceutical Group Co., Ltd.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company has a low valuation given the cash flows generated by its activity.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: DaShenLin Pharmaceutical Group Co., Ltd.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Rating Financials

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
3.05B
BB
14.09B
AA
6.36B
AAA
6.19B
AA
4.1B
AAA
3.17B
BBB
2.81B
AAA
2.78B -
BBB
- -
2.52B - - - - -
1.61B - - - - - - -
Average 4.67B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 603233 Stock
  4. Ratings DaShenLin Pharmaceutical Group Co., Ltd.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!